DURAGRAFT VASCULAR CONDUIT SOLUTION

DuraGraft: saphenous vein graft flushing and storage, purpose-built for the intraoperative window.

Intraoperative flushing and storage for saphenous vein grafts, from harvesting through grafting, at room temperature, for up to 4 hours.

DuraGraft is the first and only FDA De Novo granted solution for flushing and storing saphenous vein grafts during coronary artery bypass graft (CABG) surgery. It holds the harvested vein in a physiologically balanced, isotonic environment at room temperature for up to four hours, from harvest through anastomosis. It replaces the flushing and storage solution already in your workflow, with no protocol change.

INDICATION FOR USE
DuraGraft Vascular Conduit Solution is indicated for adult patients undergoing Coronary Artery Bypass Grafting surgeries and is intended for flushing and storage of the saphenous vein grafts from harvesting through grafting for up to 4 hours. DuraGraft is intended to maintain cell viability and structural integrity of vascular grafts during short-term storage at room temperature during the surgical procedure.
HOW DURAGRAFT WORKS

A physiologically balanced environment for a graft that has none.

From the moment the saphenous vein is harvested, it is without perfusion. Endothelial cell injury during harvesting and intraoperative storage contributes to oxidative damage. Saline and blood were never formulated to hold a graft in that state.

DuraGraft is a physiologically balanced, isotonic solution that maintains pH, osmolality, and ionic balance, supporting the structural integrity and cell viability of saphenous vein grafts from harvest through anastomosis.

pH BALANCE
Physiological pH 7.4
OSMOLALITY
305 mOsm/kg
ANTIOXIDANTS
L-Glutathione L-Ascorbic acid
NITRIC OXIDE PATHWAY
L-Arginine

Specific salts and organic components (normal constituents of blood) create a non-oxidizing, pH-balanced environment during the ischemic period.

SEAMLESS INTEGRATION

No protocol changes required.

DuraGraft is a two-component kit mixed at the point of use. It replaces the flushing and storage solution already in your workflow and covers the entire intraoperative window. No new equipment. No complex mixing. No added steps for your OR team.
Preparation
Simple two-component mix at point of use
Storage
Up to 4 hours at room temperature
Single Use
Intraoperative flush and storage

Evidence behind the solution.

Randomized trial
Within-patient comparison, 7 centers, MDCT at 12 months
2,964 patients
European DuraGraft Registry: 45 centers, 8 countries
DEN230002

FDA De Novo review: preclinical viability and morphology

REGULATORY STATUS

Two FDA authorizations, and no competing cleared product.

DuraGraft holds two separate FDA authorizations. The De Novo grant created a new device classification for intraoperative vein graft protection. The later 510(k) clearance added room temperature storage, which takes the product out of the cold chain and onto the OR shelf, supplied through hospital procurement channels rather than the pharmacy pathway. No competing FDA-cleared product exists for this indication.

Oct 2023

FDA De Novo granted. DEN230002, Class II. The first device classification of its kind for intraoperative vein graft protection.

Apr 2024

510(k) clearance for room temperature storage at 20 to 25°C (68 to 77°F), eliminating the cold chain.

Rx Only

Prescription use. Two-component kit mixed at the point of use, covering the entire intraoperative window.

PATIENT & HOSPITAL VALUE

Measurable patient and hospital value from day one.

All benefits below are listed in the Instructions for Use, as provided by the FDA to the Company. Wall thickness is a biomarker, and its clinical significance as a surrogate for long-term graft patency has not been established.

Patient benefits
  • Reduced wall thickening, the earliest detectable sign of vein graft disease
  • Prevention of oxidative damage, slowing progression of vein graft failure
  • Oxidative damage is the primary mediator of ischemic reperfusion injury
  • Reduction of oxidative damage maintains the structural and functional integrity of vascular conduits
  • Associated with lower mortality at 3 years in an observational propensity-matched comparison (Caliskan et al., 2024). This does not establish causation.
Hospital and physician benefits
  • Increased storage time of 4 hours at controlled room temperature, 20 to 25°C (68 to 77°F)
  • No change in training or surgical procedure. Seamless integration, no protocol changes required
  • Increased savings through reduction of repeat procedures and hospital stays
  • Readily available in the operating suite. Direct OR shelf placement drives adoption and increases utilization
  • Sold directly through hospital procurement channels rather than the hospital pharmacy pathway
  • No cold warehouse storage or shipping, with substantial cost savings passed to distributors and end users
FREQUENTLY ASKED QUESTIONS

Clinical

Neither saline nor autologous blood is FDA-indicated, quality-controlled, or specifically formulated for vein graft flushing and storage. DuraGraft is purpose-built and validated for this exact use.
Endothelial injury during the intraoperative window is linked to intimal hyperplasia and reduced long-term patency. DuraGraft is formulated to protect the endothelium during this window.

Regulatory & access

DuraGraft holds FDA De Novo classification (Class II) for the flushing and storage of saphenous vein grafts during CABG.
DuraGraft has been evaluated in a randomized trial and a 2,964-patient registry with a well-characterized safety profile. See our Clinical Evidence page for details.
Reach out to our team to discuss adoption, Value Analysis Committee materials, and kit ordering.

Make DuraGraft part of your CABG protocol.